Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

David Burden; Yukari Okubo; Min Zheng; Diamant Thaci; Peter van de Kerkhof; Na Hu; Christian Thoma; Siew Eng Choon

doi:10.25251/skin.7.supp.121

David Burden
Yukari Okubo
Min Zheng
Diamant Thaci
Peter van de Kerkhof
Na Hu
Christian Thoma
Siew Eng Choon

Keywords

Subgroup Analysis, Generalized Pustular Psoriasis, Spesolimab, Treatment Efficacy

References

1. Navarini AA, et al. J Eur Acad Dermatol Venereol 2017;31:1792–1799

2. Fujita H, et al. J Dermatol 2018;45:1235–1270

3. Bachelez H, et al. N Engl J Med 2021;385:2431–2440

4. Choon SE, et al. BMJ Open 2021;11:e043666.

Poster PDF

Published

Mar 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.121

How to Cite

Burden, D., Okubo, Y., Zheng, M., Thaci, D., van de Kerkhof, P., Hu, N., Thoma, C., & Choon, S. E. (2023). Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study. SKIN The Journal of Cutaneous Medicine, 7(2), s121. https://doi.org/10.25251/skin.7.supp.121

Issue

Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Section

Posters from 2023 WCH Dermatology Conference: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley, Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Lluis Puig, Siew Eng Choon, Alice Gottlieb, Slaheddine Marrakchi, Jörg Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda Gooderham, Global consensus on the clinical course, treatment and management of generalized pustular psoriasis (GPP) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley, Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Joe Merola, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, April Armstrong , Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Neil Korman, Thierry Passeron, Kenneth Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Diamant Thaçi, Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

1 2 3 4 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)